Weekly Paclitaxel, Carboplatin, and Cetuximab as First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma for Patients Ineligible to Cisplatin-Based Chemotherapy: A Retrospective Monocentric Study in 60 Patients.

Fiche publication

Date publication

janvier 2021

Journal

Frontiers in oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BOREL Christian , Dr GUIHARD Sébastien , Dr JUNG Alain , Pr PETIT Thierry , Dr DEMARCHI Martin , Dr COLIAT Pierre , Dr BURGY Mickaël

Tous les auteurs :
Carinato H, Burgy M, Ferry R, Fischbach C, Kalish M, Guihard S, Brahimi Y, Flesch H, Bronner G, Schultz P, Frasie V, Thiéry A, Demarchi M, Petit T, Jung AC, Wagner P, Coliat P, Borel C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/34778031

Résumé

For most patients suffering from recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC), chemotherapy is the main option after considering surgery and reirradiation. Cetuximab combined with a platinum-fluorouracil regimen (EXTREME) has been the standard of care for over a decade. Nevertheless, a significant number of patients remain unfit for this regimen because of age, severe comorbidities, or poor performance status. The aim of this study is to investigate an alternative regimen with sufficient efficacy and safety.